Bioequivalence of Fluzoparib(SHR3162) Study on Healthy Chinese Adult Subjects
Status:
Completed
Trial end date:
2019-09-05
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the bioequivalence of two different
specification of reference preparation capsules (10 mg/capsule, 40 mg/capsule and 100
mg/capsule, 1 capsule each) and test preparations capsules (50 mg/capsule×3). Two different
specifications of fluzoparib was provided by Jiangsu HengRui Pharmaceutical Co., Ltd.
The secondary objective of the study is to evaluate the safety of test preparations and
reference preparation fluzoparib capsules of different specifications in healthy subjects.